BioNTech SE (BNTX)
NASDAQ: BNTX
· Real-Time Price · USD
98.74
-0.33 (-0.33%)
At close: May 23, 2025, 3:59 PM
98.68
-0.06%
After-hours: May 23, 2025, 05:21 PM EDT
-0.33% (1D)
| Bid | 96.86 |
| Market Cap | 23.74B |
| Revenue (ttm) | 2.75B |
| Net Income (ttm) | -768.64M |
| EPS (ttm) | -3.59 |
| PE Ratio (ttm) | -27.5 |
| Forward PE | -16.61 |
| Analyst | Buy |
| Ask | 99.4 |
| Volume | 540,289 |
| Avg. Volume (20D) | 1,118,688 |
| Open | 97.54 |
| Previous Close | 99.07 |
| Day's Range | 96.38 - 98.86 |
| 52-Week Range | 76.53 - 131.49 |
| Beta | 1.36 |
About BNTX
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol BNTX
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for BNTX stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts4 days ago
+4.01%
Shares of vaccine stocks are trading higher follow...
Unlock content with
Pro Subscription
1 month ago
-0.76%
Shares of vaccine stocks are trading lower after CDC advisers begins a review of vaccine guidelines and discussed a more narrow use of COVID-19 booster shots.
2 weeks ago · seekingalpha.com
BioNTech: mRNA Challenges Amid Regulatory Uncertainty (Rating Downgrade)BioNTech maintains strong cash reserves (€15.85B) despite widening losses as COVID revenues decline and R&D expenses increase. BNT327 (PD-L1/VEGF-A bispecific) advances to Phase 3 trials, but shares d...
